Stocks Health care SPRO

NASDAQ · Health care

Spero Therapeutics, Inc. (SPRO)

Spero Therapeutics, Inc. brought in $47M of revenue over the twelve months to June 30, 2026, down 3.3% from a year earlier. Net income was $7.4M, a net margin of 15.7%. At June 30, 2026 it held $50.8M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 12, 2026.

What Spero Therapeutics, Inc. does

Spero Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker SPRO.

Revenue and profit by year

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Where SPRO ranks in Health care

Latest fiscal year of every company in the sector with the figure reported. Revenue is ranked among companies reporting in US dollars; growth and margins among companies with at least 10 million of revenue. Health care

Latest SEC filings

What Spero Therapeutics, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

1. August 28, 2026
   Material agreement 8-K
2. August 28, 2026
   Shelf registration to sell securities S-3
3. August 12, 2026
   Quarterly results 8-K
4. August 12, 2026
   Quarterly report 10-Q · period to June 30, 2026
5. July 14, 2026
   Material agreement 8-K
6. June 25, 2026
   Executive or director change 8-K
7. June 23, 2026
   Employee stock plan registration S-8
8. June 22, 2026
   Investor disclosure 8-K
9. May 13, 2026
   Quarterly report 10-Q · period to March 31, 2026
10. May 13, 2026
    Quarterly results 8-K

Recent insider filings (Forms 3, 4 and 144): 10, the latest on August 6, 2026. Insider transactions on SEC

Insider trades

What the people running Spero Therapeutics, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.

No insider trades were reported in the last 90 days.

All insider filings on SEC.gov · Where insiders are buying across the market

All filings on SEC EDGAR

Questions about SPRO

What does Spero Therapeutics, Inc. do?

Spero Therapeutics, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker SPRO.

Is Spero Therapeutics, Inc. profitable?

Yes. Over the twelve months to June 30, 2026 it reported net income of $7.4M on revenue of $47M, a net margin of 15.7%.

How much revenue does Spero Therapeutics, Inc. make?

Over the twelve months to June 30, 2026 Spero Therapeutics, Inc. reported revenue of $47M. That is 3.3% less than a year earlier.

When did Spero Therapeutics, Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 12, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the material agreement from August 28, 2026.

Similar companies

Compare SPRO with

Compare SPRO with any company

Follow SPRO

Get an email when Spero Therapeutics, Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow SPRO: get an email when it files

Where the numbers come from

Financial figures are the values Spero Therapeutics, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.